Wendell David Associates Inc. Sells 205 Shares of Zoetis Inc. $ZTS

Wendell David Associates Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,772 shares of the company’s stock after selling 205 shares during the quarter. Wendell David Associates Inc.’s holdings in Zoetis were worth $900,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after buying an additional 189,287 shares during the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Northern Trust Corp grew its stake in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after buying an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after buying an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. grew its stake in shares of Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after buying an additional 312,746 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.6%

Shares of NYSE ZTS opened at $144.15 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market capitalization of $63.88 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 2.32 and a beta of 0.90. The stock has a 50 day moving average price of $148.73 and a 200 day moving average price of $153.69. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $193.49.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ZTS shares. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.